PlasmaTech
Biopharmaceuticals is focused on advancing targeted treatments for the unmet
needs of critical patient care through the use of two proprietary platforms,
Salt Diafiltration Process (SDP) and Polymer Hydrogel Technology (PHT).
The
company’s SDP focuses on the extraction of therapeutic biologics, or
biopharmaceutical proteins, from human plasma. Currently, the industry standard
for the fractionation of human plasma is the Cohn Cold Ethanol Fractionation
Process, which has been in use for over 70 years. PlasmaTech’s patented method
features unusually high yields of proteins as compared with the Cohn Process,
which makes it particularly valuable in the global plasma protein market.
Intravenous Immune Globulin, which contains a broad spectrum of antibodies and
is the primary driver for manufacturers using the Cohn Process, is recovered in
much greater supply (at least 20 percent more) using the company’s proprietary
extraction method.
PlasmaTech’s
PHT platform is a patented hydrogel delivery system that uses a unique aqueous
pseudoplastic liquid to enable extended delivery of drugs to the mouth and
upper gastrointestinal tract.
Through
the use of these platforms, the company has been able to develop a robust
product pipeline that includes two commercial stage products, as well as
multiple products currently in development. MuGard™ is a mucoadhesive rinse
that provides a protective coating to prevent trauma to oral mucosae, which are
a common complication of cancer chemotherapy or radiation therapy to the head
and neck region. ProctiGard™ is a treatment for rectal mucositis, which is a
debilitating side effect most commonly associated with the treatments of
cervical, colon and prostate cancers.
The
company’s two primary platforms provide plenty of room for potential growth in
the future. The plasma protein market is estimated to be greater than $12
billion, and continued growth of approximately 10 percent annually puts
PlasmaTech in a great position to capitalize on the industry’s eventual
replacement of the antiquated Cohn fractionation process. As a critical plasma
supply shortage looms, the industry is scrambling to increase yields and
address supply constraints, both of which are possible through the use of the
company’s unique SDP.
With
an increasingly strong strategic position in the plasma protein market and
recently approved status for two commercial products, the immediate future
appears to be exceedingly bright for PlasmaTech.
For
more information, visit www.plasmatechbio.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
